Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2018 | Research article

Inhibition of RANKL-stimulated osteoclast differentiation by Schisandra chinensis through down-regulation of NFATc1 and c-fos expression

Authors: Eun-Jung Kim, Haesu Lee, Mi Hye Kim, Woong Mo Yang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Abstract

Background

Schisandra chinenesis (SC) has been reported to have ameliorative effect on osteoporosis. However, the mechanisms underlying the anti-osteoporosis activity of SC have not been clearly elucidated. In the present study, we determined the effects of SC on The receptor activator of NF-kB ligand (RANKL)-induced osteoclastogenesis and its potential mechanism.

Methods

Raw 264.7 cells were treated with 0.6, 6 and 60 μg/mL SC in the presence of 100 ng/mL RANKL for 7 days. RANKL-induced osteoclast formation was analyzed by tartrate resistant acid phosphatase (TRAP) staining. The osteoclast differentiation-related factors were confirmed along with TNF-α.

Results

SC inhibits the RANKL-induced osteoclast differentiation in dose-dependent manner within non-toxic concentrations. The supernatant concentrations of TNF-α were significantly decreased by SC treatment. In addition, osteoclastogenesis-related factors, TRAP6 and NF-κB, were markedly decreased by SC in RANKL-induced osteoclasts. Mechanistically, SC reduced the RANKL-triggered NFATc1 and c-fos expressions.

Conclusions

Taken together, our data suggest that SC can modulate bone metabolism by suppressing RANKL-induced osteoclast differentiation.

Available only for authorised users

Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.CrossRef

Gruber H, Ivey J, Thompson E, Chesnut C 3rd, Baylink D. Osteoblast and osteoclast cell number and cell activity in postmenopausal osteoporosis. Miner Electrol Metab. 1985;12(4):246–54.

Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, Ferracini R. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J. 2005;19(2):228–30.CrossRef

Sakellari D, Menti S, Konstantinidis A. Free soluble receptor activator of nuclear factor-κb ligand in gingival crevicular fluid correlates with distinct pathogens in periodontitis patients. J Clin Periodontol. 2008;35(11):938–43.CrossRef

Neale S, Smith R, Wass J, Athanasou N. Osteoclast differentiation from circulating mononuclear precursors in Paget’s disease is hypersensitive to 1, 25-dihydroxyvitamin D 3 and RANKL. Bone. 2000;27(3):409–16.CrossRef

Hirayama T, Danks L, Sabokbar A, Athanasou N. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology. 2002;41(11):1232–9.CrossRef

Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors. J Exp Med. 1999;190(12):1741–54.CrossRef

Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2(4):389–406.CrossRef

Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem. 1998;273(43):28355–9.CrossRef

10.

Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 1997;12(6):869–79.CrossRef

11.

Lacey D, Timms E, Tan H-L, Kelley M, Dunstan C, Burgess T, Elliott R, Colombero A, Elliott G, Scully S. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–76.CrossRef

12.

Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M. A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone loss. J Clin Invest. 2006;116(6):1525–34.CrossRef

13.

Chae H-S, Kang O-H, Oh Y-C, Choi J-G, Keum J-H, Kim S-B, Kim Y-S, Mun S-H, Shin D-W, Han S-H. Gomisin N has anti-allergic effect and inhibits inflammatory cytokine expression in mouse bone marrow-derived mast cells. Immunopharm Immunot. 2011;33(4):709–13.CrossRef

14.

Szopa A, Ekiert R, Ekiert H. Current knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese magnolia vine) as a medicinal plant species: a review on the bioactive components, pharmacological properties, analytical and biotechnological studies. Phytochem Rev: Pr Phyt Soc. 2017;16(2):195–218.CrossRef

15.

Nakajima K, Taguchi H, Ikeya Y, Endo T, Yosioka I. Constituents of Schizandra chinensis Baill. XIII. Quantitative analysis of lignans in the fruits of Schizandra chinensis Baill. By high performance liquid chromatography. Yakugaku Zasshi. 1983;103(7):743.CrossRef

16.

Caichompoo W, Zhang QY, Hou TT, Gao HJ, Qin LP, Zhou XJ. Optimization of extraction and purification of active fractions from Schisandra chinensis (Turcz.) and its osteoblastic proliferation stimulating activity. Phytother Res. 2009;23(2):289–92.CrossRef

17.

Kim MH, Choi YY, Han JM, H-S L, Hong SB, S-G L, Yang WM. Ameliorative effects of Schizandra chinensis on osteoporosis via activation of estrogen receptor (ER)-α/−β. Food Funct. 2014;5(7):1594–601.CrossRef

18.

Kang Y-S, Han M-H, Hong S-H, Park C, Hwang H-J, Kim BW, Kyoung KH, Young Whan Choi CMK, Choi YH. Anti-inflammatory effects of Schisandra chinensis (Turcz.) Baill fruit through the inactivation of nuclear factor-κB and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated murine macrophages. J Cancer Prev. 2014;19(4):279–87.CrossRef

19.

Guo LY, Hung TM, Bae KH, Shin EM, Zhou HY, Hong YN, Kang SS, Kim HP, Kim YS. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol. 2008;591(1):293–9.CrossRef

20.

Oh S-Y, Kim YH, Bae DS, Um BH, Pan C-H, Kim CY, Lee HJ, Lee JK. Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of Schisandra chinensis. Biosci Biotechnol Biochem. 2010;74(2):285–91.CrossRef

21.

He Y, Zhang Q, Shen Y, Chen X, Zhou F, Peng D. Schisantherin a suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways. Biochem Bioph Res Co. 2014;449(3):344–50.CrossRef

22.

Lu Y, Chen D-F. Analysis of Schisandra chinensis and Schisandra sphenanthera. J Chromatogr. 2009;1216(11):1980–90.CrossRef

23.

Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–8.CrossRef

24.

Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem. 2001;83(1):70–83.CrossRef

25.

Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007;282(25):18245–53.CrossRef

26.

Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, Sakurai N. Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol. 2002;22(4):992–1000.CrossRef

27.

Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143(1):123–50.CrossRef

28.

Kaji K, Katogi R, Azuma Y, Naito A, Inoue JI, Kudo A. Tumor necrosis factor α-induced Osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res. 2001;16(9):1593–9.CrossRef

29.

Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 1997;11(24):3482–96.CrossRef

30.

Lee ZH, Kim H-H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Bioph Res Co. 2003;305(2):211–4.CrossRef

31.

Bruzzaniti A, Baron R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 2006;7(1–2):123–39.PubMed

32.

Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem. 2000;275(40):31155–61.CrossRef

33.

Lee J-H, Jin H, Shim H-E, Kim H-N, Ha H, Lee ZH. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-κB signal. Mol Pharmacol. 2010;77(1):17–25.CrossRef

34.

David J-P, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci. 2002;115(22):4317–25.CrossRef

35.

Grigoriadis AE, Wang Z-Q, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF. C-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994;266(5184):443–9.CrossRef

36.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, J-I I. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901.CrossRef

37.

Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21(4):233–41.CrossRef

38.

Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261–9.CrossRef

39.

Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7(4):292–304.CrossRef

40.

Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638–49.CrossRef

41.

Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, Asahara H, Ohya K, Yamaguchi A, Takai T. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med. 2006;12(12):1410–6.CrossRef

Title: Inhibition of RANKL-stimulated osteoclast differentiation by Schisandra chinensis through down-regulation of NFATc1 and c-fos expression
Authors: Eun-Jung Kim
Haesu Lee
Mi Hye Kim
Woong Mo Yang
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-018-2331-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Inhibition of RANKL-stimulated osteoclast differentiation by Schisandra chinensis through down-regulation of NFATc1 and c-fos expression

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Rhaponticum acaule (L) DC essential oil: chemical composition, in vitro antioxidant and enzyme inhibition properties

Regulatory effect of Phikud Navakot extract on HMG-CoA reductase and LDL-R: potential and alternate agents for lowering blood cholesterol

Complementary medicine products used in pregnancy and lactation and an examination of the information sources accessed pertaining to maternal health literacy: a systematic review of qualitative studies

Chemical composition, antioxidant, antimicrobial and Antiproliferative activities of essential oil of Mentha spicata L. (Lamiaceae) from Algerian Saharan atlas

Somatic experiencing® for patients with low back pain and comorbid posttraumatic stress disorder – protocol of a randomized controlled trial

Herbal formula YGJDSJ inhibits anchorage-independent growth and induces anoikis in hepatocellular carcinoma Bel-7402 cells